Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clearside Biomedical excels in 2022, eyes trial milestones and partnerships

Clearside Biomedical's strong performance in 2022, supported by key achievements and financial stability, positions the company well for future growth and innovation.
While facing challenges such as trial design adjustments and addressing analyst inquiries, Clearside's strategic partnerships and upcoming trials offer significant opportunities for expansion and market advancement.

Clearside Biomedical reports positive OASIS trial results and financial stability

Clearside Biomedical's Q1 2023 performance reflects advancements in CLS-AX development and financial stability
Challenges include addressing analyst inquiries and potential resistance to extended duration treatments
Opportunities lie in leading treatment innovation and expanding investor engagement through conferences and filings

Clearside Biomedical advances in wet AMD treatment with innovative approach

Clearside Biomedical's Q2 2023 earnings call highlighted strong progress in their lead program, financial stability, and innovative delivery technology, positioning them well in the market.
The company's differentiated mechanistic approach and potential for combination therapies offer competitive advantages and opportunities for market expansion.
While facing challenges in proving efficacy, financial sustainability, and market adoption, Clearside's strategic collaborations and diverse portfolio present avenues for growth and success.

Clearside Biomedical advances trials and partnerships, eyes growth opportunities

Clearside Biomedical's Q3 2023 Earnings Call highlighted progress in trials, partnerships, and cash position. Challenges include trial enrollment and design considerations, while opportunities exist in value creation and milestone achievements by partners.

Clearside Biomedical reports positive 2023 progress and financial stability

Clearside Biomedical made significant progress in 2023, with a focus on advancing key clinical programs and collaborations.
Financially, the company is well-positioned with sufficient resources to support operations until the third quarter of 2025.
Challenges lie in successfully completing ongoing trials and maintaining competitiveness in the evolving landscape of vision treatments.
Opportunities abound in innovative drug delivery approaches, therapeutic advancements, and strategic collaborations for Clearside.

Clearside Biomedical reports stable finances and bullish outlook on CLS-AX

Clearside Biomedical's Q1 2024 earnings call highlighted a stable financial position, key leadership additions, and the promising potential of CLS-AX in treating retinal diseases. Analyst inquiries underscored areas of interest and scrutiny, pointing to the company's need for continued strategic development and adherence to regulatory standards.

Clearside Biomedical reports positive trial results and strategic leadership changes

Clearside Biomedical's Q3 2024 earnings call highlighted promising trial results, financial stability, and strategic leadership changes.
The company's strengths lie in its innovative suprachoroidal platform, strong partnerships, and positive trial outcomes for wet AMD treatment.
While facing challenges in trial design and funding, Clearside Biomedical has opportunities in geographic atrophy treatment and flexible dosing strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Companies Inc

PDUFA Action Date Is October 30 , 2021 LAVAL, QC and ALPHARETTA, Ga., June 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, along with Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application for XIPERE™1 (triamcinolone acetonide suprachoroidal injectable suspension).

Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q1 2021 Results - Earnings Call Transcript

Shares of Clearside Biomedical (NASDAQ:CLSD) rose after the company reported Q1 results. Quarterly Results Earnings per share decreased 85.71% over the past year to ($0.13), which missed the estimate of ($0.10).

Recap: Clearside Biomedical Q1 Earnings

- Recent New Drug Application Resubmission for XIPERE TM

Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update

Presentations support proprietary suprachoroidal space delivery platform and programs Presentations support proprietary suprachoroidal space delivery platform and programs

Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting

ALPHARETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its first quarter 2021 financial results will be reported on Monday, May 17, 2021 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021

ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) for the treatment of macular edema associated with uveitis.

Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis

ALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at two upcoming virtual conferences in April 2021:

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q4 2020 Results - Earnings Call Transcript

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -7.69% and -98.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Lags Revenue Estimates

- OASIS Wet AMD Phase 1/2a Trial Initiated and Cohort 1 Dosing Completed -

Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Clearside Biomedical, Inc. (CLSD) Q4 Earnings Expected to Decline

- Initial Safety Data from First Cohort Expected Mid-2021 -

Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

ALPHARETTA, Ga., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its fourth quarter and full year 2020 financial results will be reported on Wednesday, March 10, 2021 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Clearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021

ALPHARETTA, Ga., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the Company will participate in two upcoming investor conferences in March 2021:

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021

For Clearside Biomedical, the onboarding of a new contract manufacturer should finally put its CRL issues for ocular therapy XIPERE in the rearview mirror. This move should pave the way for an NDA resubmission in 1H21.

Circling Back On Clearside Biomedical

ALPHARETTA, Ga., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that David M. Brown, M.D. delivered a presentation entitled, “Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD” at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Bascom Palmer Eye Institute on February 12 & 13, 2021.

Clearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program

- Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders -

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting

As of late, it has definitely been a great time to be an investor in Clearside Biomedical (CLSD).

Clearside Biomedical's (CLSD) Shares March Higher, Can It Continue?

Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.

Implied Volatility Surging for Clearside Biomedical (CLSD) Stock Options

Does Clearside Biomedical, Inc. (CLSD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Clearside Biomedical, Inc. (CLSD) is a Great Choice

ALPHARETTA, Ga., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the first patients have been enrolled in its Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD). Clinical sites, all based in the United States, are activated and currently screening wet AMD patients for this Phase 1/2a trial, known as OASIS, involving CLS-AX, a proprietary suspension of axitinib for suprachoroidal injection.

Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

ALPHARETTA, Ga., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that it has entered into a securities purchase agreement with institutional investors and certain existing stockholders, providing for the purchase and sale of 4,209,050 shares of common stock at a price of $2.851 per share, priced at-the-market under Nasdaq rules based on the five-day average closing price of the common stock, in a registered direct offering, resulting in total gross proceeds of approximately $12.0 million, before deducting the placement agent's fees and other estimated offering expenses.

Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering

Clearside Biomedical is aiming to make ocular gene therapy accessible. XIPERE NDA resubmission and potential approval in 2021 triggering a $15 million payment from partner Bausch Health.

Clearside Biomedical: SCS Microinjector Platform With Significant Upside

Apple

Caterpillar

Disney

Dow Inc

Eiger BioPharmaceuticals

Intel

Johnson & Johnson

JPMorgan Chase & Co

NIKE

Walmart

Two new breakout stocks for Week 1 of 2021 with better than 10% short-term upside potential. The MDA breakout picks completed 2020 up +73.4% beating the S&P 500 for the 4th consecutive year with avg annual returns of +43.8%.

News for Clearside Biomedical Stock (CLSD)